MX2020006398A - Compuestos y composiciones para tratar la fibrosis. - Google Patents

Compuestos y composiciones para tratar la fibrosis.

Info

Publication number
MX2020006398A
MX2020006398A MX2020006398A MX2020006398A MX2020006398A MX 2020006398 A MX2020006398 A MX 2020006398A MX 2020006398 A MX2020006398 A MX 2020006398A MX 2020006398 A MX2020006398 A MX 2020006398A MX 2020006398 A MX2020006398 A MX 2020006398A
Authority
MX
Mexico
Prior art keywords
compounds
compositions
treating fibrosis
treating
disease
Prior art date
Application number
MX2020006398A
Other languages
English (en)
Inventor
Anton Bennett
Jonathan Ellman
Haya Jamali
Karen S Anderson
Elias Lolis
Denton Hoyer
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of MX2020006398A publication Critical patent/MX2020006398A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Abstract

La presente invención proporciona compuestos y métodos para tratar la enfermedad modulada por MKP-5; en ciertas modalidades, la enfermedad modulada por MKP-5 es una enfermedad fibrotica.
MX2020006398A 2017-12-18 2018-12-18 Compuestos y composiciones para tratar la fibrosis. MX2020006398A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607110P 2017-12-18 2017-12-18
PCT/US2018/066191 WO2019126141A1 (en) 2017-12-18 2018-12-18 Compounds and compositions for treating fibrosis

Publications (1)

Publication Number Publication Date
MX2020006398A true MX2020006398A (es) 2020-09-07

Family

ID=66993802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006398A MX2020006398A (es) 2017-12-18 2018-12-18 Compuestos y composiciones para tratar la fibrosis.

Country Status (9)

Country Link
US (2) US11504373B2 (es)
EP (1) EP3732179B1 (es)
JP (2) JP7317039B2 (es)
KR (1) KR20200100726A (es)
CN (2) CN111670188B (es)
AU (2) AU2018388549B2 (es)
CA (1) CA3085770A1 (es)
MX (1) MX2020006398A (es)
WO (1) WO2019126141A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3917514A4 (en) * 2019-01-30 2023-02-22 Yale University COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF FIBROSIS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2405725A1 (en) * 2000-04-10 2001-10-18 Merck Patent Gesellschaft Mit Beschraenkter Haftung Identification of a novel dual specificity phosphataes
US20030162230A1 (en) * 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
WO2005053732A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Biomarkers for the efficacy of somatostatin analogue treatment
WO2009137492A1 (en) 2008-05-05 2009-11-12 Abbott Laboratories Heteroaryl-fused macrocyclic pyrimidine derivatives
WO2014176488A1 (en) * 2013-04-26 2014-10-30 Indiana University Research & Technology Corporation Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2)

Also Published As

Publication number Publication date
US20200390770A1 (en) 2020-12-17
EP3732179A1 (en) 2020-11-04
CN111670188A (zh) 2020-09-15
EP3732179A4 (en) 2022-01-19
EP3732179B1 (en) 2024-05-01
WO2019126141A1 (en) 2019-06-27
AU2023204581A1 (en) 2023-10-05
CA3085770A1 (en) 2019-06-27
AU2018388549A1 (en) 2020-07-02
US11504373B2 (en) 2022-11-22
US20230181588A1 (en) 2023-06-15
JP7317039B2 (ja) 2023-07-28
CN111670188B (zh) 2023-06-23
KR20200100726A (ko) 2020-08-26
JP2023145544A (ja) 2023-10-11
AU2018388549B2 (en) 2023-06-01
CN116687934A (zh) 2023-09-05
JP2021506975A (ja) 2021-02-22

Similar Documents

Publication Publication Date Title
SG10201805246XA (en) Approximated parameter adaptation
MX2018003472A (es) Moduladores de la expresion de kras.
MX2019007021A (es) Anticuerpos il-11ra.
MX2019007020A (es) Anticuerpos il-11.
AU2018258581A8 (en) RAF-degrading conjugate compounds
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2018010971A (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
EP3757215A3 (en) Compositions and methods for modulating growth hormone receptor expression
IL280809B (en) New preparations, their use and methods of their creation
ZA201904387B (en) Compositions and methods for treating, ameliorating and preventing h. pylori
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
JOP20210050A1 (ar) معدلات تعبير pnpla3
WO2018101663A3 (ko) 생체 조직 투명화용 조성물 및 이를 이용한 생체 조직 투명화 방법
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
MX2016016073A (es) Envase facetado.
PH12019502174A1 (en) Modulators of pcsk9 expression
NZ742805A (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
GB2576614B (en) Compositions, uses and methods
GB201901099D0 (en) Methods, uses and compositions
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
GB201804163D0 (en) Uses, compositions and methods
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
IL286646A (en) Preparations, devices and methods for the treatment of Fabry disease
JOP20190164B1 (ar) تركيبات وطرق لعلاج داء فاربر
WO2017161344A8 (en) Compositions and methods for treating parasitic diseases